|
|||||
|
|
| 心房颤动口服药物治疗的新选择 | |
| 引用本文： | 陈家元,张爱东,卢红艳,李自成. 心房颤动口服药物治疗的新选择[J]. 临床心血管病杂志, 2012, 0(9): 646-648 |
| 作者姓名： | 陈家元 张爱东 卢红艳 李自成 |
| 作者单位： | 暨南大学附属第一医院心内科 |
| 基金项目： | 暨南大学第一临床医学院重点学科基金(No:暨一临【2010】4号) |
| 摘 要： | 近年来,尽管导管消融和外科手术在心房颤动(房颤)的治疗中取得了令人瞩目的进展,但并未广泛应用,药物治疗依然处于首要地位。由于传统抗凝药和抗心律失常药的自身局限性,该领域新型药物的开发成为研究热点,而近年来多种新型口服药物的开发研制和临床试验的成功,为房颤的药物治疗带来新的希望。本文对此加以综述。 |
| 关 键 词： | 心房颤动 达比加群酯 利伐沙班 决奈达隆 |
New option in oral drug for the treatment of atrial fibrillation |
|
| CHEN Jiayuan,ZHANG Aidong,LU Hongyan,LI Zicheng. New option in oral drug for the treatment of atrial fibrillation[J]. Journal of Clinical Cardiology, 2012, 0(9): 646-648 | |
| Authors: | CHEN Jiayuan ZHANG Aidong LU Hongyan LI Zicheng |
| Affiliation: | (Department of Cardiology,First Affiliated Hospital of Jinan University,Guangzhou,510630,China) |
| Abstract: | Although catheter ablation technology and surgery treatment of atrial fibril-ation have been remarked advance in recent years,the application is limited,and drug therapy is still the first choice.Owing to the limitation of traditional anticoagulation and antiarrhyt-hmic drug,it becomes a hot spot to develop new durgs in this field.Recently the successes of development and clinic trials of novel oral anticoagulant and antiarrhythmic drugs bring a new hope for treatment of atrial fibrillation.This review discusses recent advances about these new drugs. |
| Keywords: | atrial fibrillation dabigatran etexilate rivaroxaban dronedarone |
| 本文献已被 CNKI 等数据库收录！ | |